479 related articles for article (PubMed ID: 23515956)
1. Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.
Lu Y; Yang J; Zhang H; Yang J
Clin Pharmacokinet; 2013 Jul; 52(7):567-81. PubMed ID: 23515956
[TBL] [Abstract][Full Text] [Related]
2. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
[TBL] [Abstract][Full Text] [Related]
3. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y
J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326
[TBL] [Abstract][Full Text] [Related]
4. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
[TBL] [Abstract][Full Text] [Related]
5. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D
J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667
[TBL] [Abstract][Full Text] [Related]
7. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.
Kim HS; Lee SS; Oh M; Jang YJ; Kim EY; Han IY; Cho KH; Shin JG
Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919
[TBL] [Abstract][Full Text] [Related]
8. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
10. Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.
Linder MW; Bon Homme M; Reynolds KK; Gage BF; Eby C; Silvestrov N; Valdes R
Clin Chem; 2009 Oct; 55(10):1861-8. PubMed ID: 19679631
[TBL] [Abstract][Full Text] [Related]
11. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
12. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin.
Sangviroon A; Panomvana D; Tassaneeyakul W; Namchaisiri J
Drug Metab Pharmacokinet; 2010; 25(6):531-8. PubMed ID: 20930419
[TBL] [Abstract][Full Text] [Related]
14. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
15. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
16. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin.
Yuen E; Gueorguieva I; Wise S; Soon D; Aarons L
J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):3-24. PubMed ID: 19941044
[TBL] [Abstract][Full Text] [Related]
17. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.
Tham LS; Goh BC; Nafziger A; Guo JY; Wang LZ; Soong R; Lee SC
Clin Pharmacol Ther; 2006 Oct; 80(4):346-55. PubMed ID: 17015052
[TBL] [Abstract][Full Text] [Related]
18. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
[TBL] [Abstract][Full Text] [Related]
19. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
[TBL] [Abstract][Full Text] [Related]
20. VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China.
Gu Q; Kong Y; Schneede J; Xiao YB; Chen L; Zhong QJ; Wang XF; Hao J; Chen BC; Chen JJ
Eur J Clin Pharmacol; 2010 Dec; 66(12):1217-27. PubMed ID: 20842355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
